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Abstract: Lymphoma defines a group of different diseases. This study examined pre-treatment
plasma samples from 66 adult patients (aged 20–74) newly diagnosed with any lymphoma subtype,
and 96 frequency matched population controls. We used gas chromatography-mass spectrometry
(GC-MS) to compare the metabolic profile by case/control status and across the major lymphoma
subtypes. We conducted univariate and multivariate analyses, and partial least square discriminant
analysis (PLS-DA). When compared to the controls, statistically validated models were obtained for
diffuse large B-cell lymphoma (DLBCL), chronic lymphocytic leukemia (CLL), multiple myeloma
(MM), and Hodgkin lymphoma (HL), but not follicular lymphoma (FL). The metabolomic analysis
highlighted interesting differences between lymphoma patients and population controls, allowing the
discrimination between pathologic and healthy subjects: Important metabolites, such as hypoxanthine
and elaidic acid, were more abundant in all lymphoma subtypes. The small sample size of the
individual lymphoma subtypes prevented obtaining PLS-DA validated models, although specific
peculiar features of each subtype were observed; for instance, fatty acids were most represented in
MM and HL patients, while 2-aminoadipic acid, 2-aminoheptanedioic acid, erythritol, and threitol
characterized DLBCL and CLL. Metabolomic analysis was able to highlight interesting differences
between lymphoma patients and population controls, allowing the discrimination between pathologic
and healthy subjects. Further studies are warranted to understand whether the peculiar metabolic
patterns observed might serve as early biomarkers of lymphoma.
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1. Introduction
Lymphomas represent a heterogeneous group of lymphoid malignancies with varied patterns
of clinical behavior and responses to treatment. Lymphomas rank the fifth most common cancer in
the developed world [1]. Prognosis depends on the histologic type, clinical factors, and molecular
characteristics. Lymphomas are classified based upon their histological characteristics, and the stage
of maturation of the lymphocytes from which they originate [2]. B-cell lymphomas are the most
frequently represented, and they include diffuse large B-cell lymphoma (DLBCL), chronic lymphocytic
leukemia (CLL), follicular lymphoma (FL), multiple myeloma (MM), and other less frequent subtypes.
Lymphoma classification keeps evolving thanks to new molecular tools, such as metabolomics.
Metabolomics is one of the most recent innovative technologies aiming to understand the metabolic
processes within cells, tissues, organs, and organisms. It focuses on the quantitative analysis of a large
number of metabolites, representing the end-products of genes, transcripts, and protein functions. The
strong interest in metabolomics relates to the fact that even subtle changes in genes, abundance of
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transcripts, or levels of protein can substantially change the quantity and dynamics of metabolites.
Therefore, the analysis of metabolites represents a sensitive measure of the biological status in health
or disease [3]. Altered metabolic fingerprints of lymphoma patients offer novel opportunities to
detect or identify potential risks, and ultimately help achieve the goal of “personalized medicine” [4].
In this regard, a sizable number of findings have been tested for translational applications, focusing on
lymphoma ranging from early detection to therapy prediction and prognosis [5,6].
Recently, a metabolomic approach has been proposed to identify possible biomarkers for
characterization and early diagnosis of the different lymphoma subtypes [6]. The metabolomic reports
published thus far employed different techniques, such as liquid chromatography-mass spectrometry
(LC-MS) [7–10], both gas chromatography-mass spectrometry (GC-MS) and LC-MS [11,12], or nuclear
magnetic resonance (NMR) [13–16], and different bio specimen [7–16]. In this study, a GC-MS technique
was used to analyze plasma samples from patients affected by different lymphoma subtypes, and from
age (10-year groups) and gender frequency matched population controls. The aim of the study was to
identify possible metabolic biomarkers allowing early diagnosis, and possibly differential diagnosis
between the subtypes.
2. Results
Table 1 shows the gender distribution and mean age of the study population by case-control
status. Cases are subdivided by histotypes.
Table 1. Main characteristics of the study population by case-control status and by major
lymphoma subtypes.
N
Gender Age
M F M/F Mean sd
Controls 96 50 46 1.09 57.0 12.87
Diffuse Large B-cell Lymphoma 13 6 7 0.86 62.2 10.46
Follicular Lymphoma 8 5 3 1.67 47.9 8.36
Chronic Lymphocytic Leukaemia 6 2 4 0.50 62.0 15.23
Multiple Myeloma 9 5 4 1.25 61.7 7.00
Other B-cell Lymphoma 14 10 4 2.50 59.7 7.92
B-cell Lymphoma (total) 50 28 22 1.27 59.1 10.52
Hodgkin Lymphoma 10 4 6 0.67 38.2 12.22
T-cell Lymphoma 2 2 0 - 59.5 -
Unspecified Lymphoma subtype 4 2 2 1.0 63.8 15.17
All lymphomas 66 36 30 1.20 57.3 13.22
We compared the metabolomic profile of patients affected by the five major B-cell lymphoma
subtypes to that detected in healthy controls using univariate t-test analysis, multivariate analysis, and
partial least square-discriminant analysis (PLS-DA). The following analyses were conducted: Diffuse
large B-cell lymphoma (DLBCL) (13 samples vs 42 controls), follicular lymphoma (FL) (8 samples vs
34 controls), chronic lymphocytic leukemia (CLL) (6 samples vs 29 controls), multiple myeloma (MM)
(9 samples vs 36 controls), and Hodgkin lymphoma (HL) (10 samples vs 36 controls). Table 2 shows
the results of the univariate analysis.
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Table 2. Differences in plasma metabolites between the major lymphoma subtypes and the controls: Results of the univariate analysis with p after false discovery rate
(FDR) < 0.05.
Metabolite
Diffuse Large B-Cell
Lymphoma (DLBCL)
Follicular Lymphoma
(FL)
Chronic Lymphocytic
Leukemia (CLL)
Multiple Myeloma
(MM)
Hodgkin Lymphoma
(HL)
p-Value FDR Trend p-Value FDR Trend p-Value FDR Trend p-Value FDR Trend p-Value FDR Trend
2-Aminoadipic acid 0.0021 0.0279 ↓ 0.00048 0.0079 ↓
2-Aminoheptanedioic acid 4.3 × 10−6 0.0004 ↓
3-Hydroxybutyric acid 0.0017 0.0279 ↑
3-Phosphoglycerate 0.00124 0.0401 ↑
A148003 9.95 × 10−5 0.0042 ↓
A203003 0.00024 0.0065 ↑
Aspartic acid 3.41 × 10−4 0.0096 ↓
Carbonic acid 0.00692 0.0405 ↑
Erythritol 0.0026 0.0279 ↑ 0.00503 0.0327 ↑
Ethanolamine 8.02 × 10−4 0.0233 ↓
Fucose 0.0045 0.0421 ↑
Glucoheptonic acid 1,4-lactone 0.0004 0.0079 ↓
Glucose 1.97 × 10−4 0.0088 ↓ 0.00374 0.0481 ↓
Glutamic acid 0.00363 0.0271 ↑
Glycine 0.0011 0.0231 ↑
Hippuric acid 7.28 × 10−5 0.0032 ↓
Hypoxanthine 1.03 × 10−5 0.0004 ↑ 0.00134 0.0401 ↑
Iminodiacetic acid 0.00338 0.0271 ↓
Inositol 0.00811 0.0443 ↑
Lactic acid 3.26 × 10−5 0.0029 ↑ 0.00257 0.0481 ↑
Linoleic acid 0.00372 0.0481 ↑
Mannose 0.0027 0.0279 ↑ 0.00104 0.0122 ↑
Ornithine 0.0093 0.0476 ↑
Palmitic acid 0.00286 0.0481 ↑
Phosphate 8.7 × 10−4 0.0401 ↑
Proline+CO2 0.006 0.0455 ↓
Quinic acid 2.91 × 10−5 0.0025 ↓
Tryptophan 0.00074 0.0102 ↑
Unknown 1314 8.30 × 10−6 0.0004 ↓
Unknown 1342 0.00519 0.0327 ↑
Unknown 2028 0.00344 0.0271 ↓
Uric acid 0.01032 0.0498 ↑
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The PLS-DA identified four cross-validated models. Table 3 shows the results, and Figure 1 reports
the corresponding score plots. The variable importance in projection (VIP) score plots are reported
as Supplementary Figures S1–S4. As shown in Table 3, the PLS-DA discriminating ability from the
controls was maximum for CLL (Q2 = 0.734). The comparison between FL and control samples did
not result in significant differences in respect to the controls (Q2 = 0.131), and therefore will not be
discussed further. For each comparison, the PLS-DA analysis identified the most important metabolites
in the class discrimination. Table 4 shows the relative abundance differences of the most important
metabolites for the different comparisons.
Table 3. Partial least square-discriminant analysis (PLS-DA) parameters for the comparison of different
lymphomas with controls (C).
Comparison Number of Components Accuracy R2 Q2
DLBCL/C 2 0.945 0.845 0.600
FL/C 5 0.857 0.973 0.131
CLL/C 2 1.00 0.911 0.734
MM/C 4 0.933 0.949 0.613
HL/C 4 0.935 0.950 0.679
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Table 4. PLS-DA most important metabolites (VIP = variable importance in the projection; VIP score >
1) and the relative abundance differences: ↑more abundant in lymphoma compared to controls; ↓ less
abundant in lymphoma compared to controls.
Metabolite Class e HMDB ID CAS DLBCL CLL MM HL
2-Aminoadipic acid a AA HMDB0000510 7620-28-2 ↓ ↓
2-Aminoheptanedioic acid a AA HMDB0034252 3721-85-5 ↓ ↓ ↓
2-Hydroxybutyric acid c HA HMDB0000008 600-15-7 ↑ ↑
3-Aminoisobutyric acid c AA HMDB0003911 144-90-1 ↓ ↑
3-Hydroxybutyric acid c HA HMDB0000357 300-85-6 ↑
3-Phosphoglyceric acid b HA HMDB0000807 820-11-1 ↑
4-Hydroxyproline c AA HMDB0000725 51-35-4 ↑ ↑
A148003 b - - - ↓ ↓
A203003 b - - - ↑
Aspartic acid c AA HMDB0000191 56-84-8 ↓
Cis-Aconitic acid c A HMDB0000072 585-84-2 ↓ ↓
Cysteine c AA HMDB0000574 52-90-4 ↓ ↑
Elaidic acid c FA HMDB0000573 112-79-8 ↑ ↑ ↑ ↑
Erythritol c PO HMDB0002994 149-32-6 ↑ ↑
Erythronic acid b HA HMDB0000613 13752-84-6 ↑
Ethanolamine c Am HMDB0000149 141-43-5 ↓
Fructose c S HMDB0000660 53188-23-1 ↓
Fucose c S HMDB0000174 2438-80-4 ↑
Glucoheptonic acid b HA - 87-74-1 ↓ ↓
Gluconic acid c HA HMDB0000625 526-95-4 ↑ ↑ ↓
Glutamic acid c AA HMDB0000148 56-86-0 ↑ ↑ ↑
Glycerol-3-Phosphate c PO HMDB0000126 57-03-4 ↑ ↑
Glycine c AA HMDB0000123 56-40-6 ↑ ↑
Glycolic acid c HA HMDB0000115 79-14-1 ↑ ↑
Hippuric acid c A HMDB0000714 495-69-2 ↑ ↓ ↓
Hypoxanthine c P HMDB0000157 68-94-0 ↑ ↑ ↑ ↑
Iminodiacetic acid c A HMDB0011753 142-73-4 ↓
Inositol-like d PO - - ↑ ↑
Inositol phosphate a PO HMDB0002985 15421-51-9 ↑
Lactic acid c HA HMDB0000190 79-33-4 ↑
Linoleic acid c FA HMDB0000673 60-33-3 ↑
Mannitol c PO HMDB0000765 69-65-8 ↑ ↑
Monosaccharide 1886 S - - ↓ ↑
Myristic acid c FA HMDB0000806 544-63-8 ↑ ↑
Oleic acid c FA HMDB0000207 112-80-1 ↑ ↑ ↑
Ornithine c AA HMDB0000214 3184-13-2 ↑
Palmitic acid c FA HMDB0000220 57-10-3 ↑
Palmitoleic acid c FA HMDB0003229 373-49-9 ↑ ↑ ↑
Phosphate c I HMDB0001429 14265-44-2 ↓ ↑
Proline+CO2 b AA - - ↓
Pyroglutamic acid c AA HMDB0000267 98-79-3 ↑
Pyrophosphate a I HMDB0000250 14000-31-8 ↓
Quinic acid b HA HMDB0003072 77-95-2 ↓ ↓
Serine c AA HMDB0000187 56-45-1 ↑
Serotonin a Am HMDB0000259 50-67-9 ↓
Stearic acid c FA HMDB0000827 57-11-4 ↑ ↑
Succinic acid c A HMDB0000254 110-15-6 ↑ ↑
Sucrose c S HMDB0000258 57-50-1 ↓
Threitol c PO HMDB0004136 2418-52-2 ↑ ↑ ↓
Tryptophan c AA HMDB0000929 73-22-3 ↓ ↑
Unknown 1314 - - - ↓
Unknown 1910 - - - ↑ ↑ ↑
Unknown 2028 - - - ↓ ↓
Uric acid c P HMDB0000289 69-93-2 ↓ ↑ ↑ ↓
a Identified by NIST (matching factor >70%). b Identified by GMD (matching factor >70%). c Identified by in-house
library. d Inositol structural isomer other than myo-inositol, chiro-inositol, scyllo-inositol. e Chemical class: AA
(Amino acid), HA (Hydroxy acid), A (Acid), FA (Fatty acid), PO (Polyol), Am (Amine), S (Sugar), P (Purine),
I (Inorganic).
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Two metabolites were more abundant in all lymphoma subtypes compared to the controls:
Hypoxanthine and elaidic acid. Another interesting feature was the number of metabolites showing a
common behavior across the different lymphoma subtypes. In particular, eight metabolites showed
a similar upward or downward change in DLBCL and CLL cases compared to the controls, namely
2-aminoadipic acid, 2-aminoheptanedioic acid, 4-hydroxyproline, erythritol, glucoheptonic acid,
inositol-like (an inositol isomer other than myo-, scyllo- and chiro-inositol), threitol, and unknown
1910. Among these, 2-aminoadipic acid/2-aminoheptanedioic acid (common name 2-aminopimelic
acid), and erythritol/threitol are chemically closely related (Figure 2).
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In fact, 2-aminoadipic and 2-aminoheptanedioic acids are α-amino bicarboxylic acids differing by
only one carbon (i.e., they are homologous), and both were less abundant in DLBCL and CLL patients
compared to the controls. Threitol and erythritol are four-carbon polyols differing by the configuration
of only one chiral carbon (i.e., they are diastereomers), and both were more abundant in DLBCL and
CLL cases compared to the controls.
Eight other metabolites showed similar changes in MM and HL cases compared to the controls,
namely cis-aconitic acid, glutamic acid, hippuric acid, myristic acid, oleic acid, palmitoleic acid, and
stearic acid. All these metabolites are carboxylic acids; four are fatty acids, two saturated and two
unsaturated. All the four fatty acids were more abundant in MM and HL patients compared to
the controls.
3. Discussion
We analyzed the metabolome of plasma samples from patients of five lymphoma subtypes
and healthy controls by untargeted GC-MS. We obtained a significant PLS-DA model for four out
of the five major lymphoma subtypes. A common feature of the four significant models was the
relative abundance of hypoxanthine and elaidic acid among the patients in respect to the controls.
Hypoxanthine is a purine involved in adenine and guanine metabolism and, therefore, in the synthesis
of the corresponding nucleosides. In this regard, Yoo found low amounts of hypoxanthine in the urine
of non-Hodgkin lymphoma (NHL) patients [7], while plasma levels were elevated in children with
acute lymphoblastic leukemia (ALL) or NHL: In these patients, treatment with high-dose methotrexate
lowered hypoxanthine levels [17]. Serum hypoxanthine levels were also elevated in a heterogeneous
group of hemolymphatic malignancies, including acute myeloid leukemia, NHL and CLL [14], and in
rectal cancer patients who underwent chemoradiotherapy [18]. Uric acid, another purine metabolite,
showed higher levels in CLL and MM, and lower in DLBCL and HL when compared to the controls.
Uric acid is the end-product of the purine oxidative degradation, deriving from hypoxanthine through
xanthine by a NAD-dependent oxidoreductase (https://www.genome.jp/dbget-bin/www_bget?rn:
R01768; https://www.genome.jp/dbget-bin/www_bget?rn:R02103).
Elaidic acid is the trans isomer of monounsaturated C18 oleic acid, naturally present in ruminant
fat, meat, margarine, and baked products [19]; its plasma level has been associated with an increase
in total mortality and in cardiovascular mortality [20], and a diet high in trans fatty acids has been
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associated with an increase in NHL risk [21]. Herein, for the first time, we report that elaidic acid
plasma level is more elevated in lymphoma patients, likewise in the four subtypes we could investigate,
compared to the controls.
Other fatty acids, such as myristic, oleic, palmitoleic, and stearic acid were more represented in
both MM and HL, and plasma samples from HL patients were also characterized by an increased
amount of linoleic and palmitic acid. Dysregulation of fatty acid metabolism in cancer cells is well
known [22,23] as it is the potential of fatty acid synthase (FAS) as a drug target; in fact, FAS was
expressed above normal in MM [24] and CLL [25,26].
Glycine was more abundant in plasma samples of DLBCL and HL cases compared to the controls.
How this observation matches the reported impairment in intracellular glycine transport in DLBCL
patients [9] is still unclear. A connection has been suggested between defective intracellular glycine
import and increase in tetrahydrofolate-bound one-carbon unit production resulting from conversion
from serine to glycine by serine hydroxymethyltransferase (SHMT) [9]; the hypothesis is worth
exploring, as previous studies have shown the relevance of one-carbon metabolism and changes in the
methylation pattern in the etiology of lymphoma subtypes [27,28].
2-aminoadipic acid was reported at increased levels in patients with carcinoma of the prostate [29],
and it was tentatively proposed as a biomarker of glioblastoma aggressiveness [30]. The finding of a
higher level of its homologous 2-aminoheptanedioic acid in the cerebrospinal fluid of glioblastoma
patients, compared to that of grade I–II and grade III glioma patients [31], and in fecal samples from
colorectal cancer patients [32] would support the proposal. On the contrary, levels of the same fatty
acids were lower in plasma samples of DLBCL and CLL patients than in controls, and 2-aminoadipic
acid was lower in colorectal cancer tissue in respect to the adjacent normal mucosa [33].
Recently, erythritol, a four-carbon bacterial metabolite [34], has been identified as an endogenous
human metabolite derived from glucose-6-phosphate in the pentose phosphate pathway (PPP) [35],
which would link its production to obesity in young adults. In the present study, erythritol and threitol
were more abundant in DLBCL and CLL cases: The links between these metabolites and the PPP
would suggest a disorder of the glucose catabolic pathway in these lymphoma subtypes.
Consistent with previous reports [14], CLL cases had an elevated level of 2-hydroxybutyric acid, a
by-product in the synthesis of glutathione from cystathionine under oxidative stress condition. This
four-carbon hydroxy acid was also increased in plasma from hepatocellular carcinoma cases [36], and
it was suggested as a potential biomarker of insulin resistance and impaired glucose regulation [37,38].
Our study has several limitations. First, the small sample size did not allow discrimination
between the individual major lymphoma subtypes based on their peculiar metabolic features, although
we could identify specific metabolic imprints for each in respect to the healthy controls. All patients
donated their blood before undergoing treatment, so that we could be reasonably confident that what
we observed was in fact a disease effect. Only large-scale follow-up studies in the general population
might help in understanding whether the metabolic changes observed could also be predictive of a
developing lymphoma in its early stage. Secondly, we performed a large number of comparisons,
which might have resulted in a proportionally elevated number of chance findings. However, we
corrected p-values using the false discovery rate technique, and we interpreted our results consequently,
based also on their consistency with previous literature reports.
In spite of such limitations, we think our findings warrant replication in larger pooled analyses.
4. Materials and Methods
4.1. Study Population
During 2012–16, we recruited incident adult patients (aged 20–74) with a first diagnosis of
lymphoma at the hematology unit of the A. Businco Hospital in Cagliari—the main referral center for
oncohematology in southern Sardinia, Italy—to participate in a case-control study on gene-environment
interactions in the etiology of lymphoma. The pathologists collaborating to the study reviewed the
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clinical diagnosis of lymphoma using the 2008 World Health Organization (WHO) classification of
lymphoma. All lymphoma subtypes, including B-cell and T-cell lymphomas, and Hodgkin lymphoma
were included. Controls were a random sample of the resident population in southern Sardinia, the
referral area of the hematology department of the oncology hospital. Controls were frequency matched
to the cases by gender, 10-year age group, and local health unit of residence. Patients affected by
infectious diseases and suffering from immune system disorders were ineligible to serve as controls.
Following the Helsinki protocol, all study subjects provided written consent to the use of their
biological samples before participation, in which they acknowledged that their samples would have
been fully anonymized, and their identity could not be identified via the papers or in the databases.
The study protocol included an in-person interview, conducted by trained interviewers at the hospital
or the residence home; at the end of the interview, subjects were requested to donate a 40 mL blood
sample to investigate genetic and epigenetic determinants of disease. Overall, samples were available
for 196 cases and 151 controls; after storing plasma samples for the main analyses originally planned,
aliquots for 66 cases and 96 controls remained available to study the metabolic profile of lymphoma
subtypes, with reference to the controls. After collection, blood samples were centrifuged, and plasma
samples were aliquoted and stored at −80 ◦C until metabolomic analysis.
4.2. Samples Preparation and GC-MS Analysis
The analytical method has been described elsewhere [39], but it was slightly modified for the
purposes of the present study. In brief, 400 µL plasma aliquots were treated with 1200 µL of cold
methanol in 2 mL Eppendorf tubes, vortex mixed, and centrifuged 10 min at 14,000 rpm (16.9 G).
400 µL of the upper phase were transferred in glass vials (1.5 mL) and evaporated to dryness overnight
in an Eppendorf vacuum centrifuge. 50 µL of a 0.24 M (20 mg/mL) solution of methoxylamine
hydrochloride in pyridine was added to each vial, samples were vortex mixed, and left to react for 17 h
at room temperature in the dark. Then 50 µL of MSTFA (N-Methyl-N-trimethyl-silyltrifluoroacetamide)
were added and left to react for 1 h at room temperature. Samples were subsequently diluted
with hexane (100 µL), with tetracosane (0.01 mg/mL) as the internal standard, just before GC-MS
analysis. Analyses were performed on an Agilent 5977B GC/MS interfaced to the GC 7890B (Agilent
Technologies, Palo Alto, CA, USA), equipped with a DB-5ms column (Agilent J&W Scientific, Folsom,
CA, USA). Injector temperature was 230 ◦C, detector temperature 280 ◦C, helium carrier gas flow
rate of 1 mL/min. GC oven temperature program was the following: 90 ◦C initial temperature, 1 min
hold time, increasing 10 ◦C/min to a final temperature of 270 ◦C, 7 min hold time. Samples (1 µL)
were injected in split (1:4) mode. After a solvent delay of 3 min, mass spectra were acquired in
full scan mode using 2.28 scans/s with a mass range of 50–700 Amu. Each acquired chromatogram
was analyzed by means of the free software AMDIS (Automated Mass spectral Deconvolution and
Identification System) (http://chemdata.nist.gov/mass-spc/amdis), that identifies each chromatographic
peak by comparison of the relative mass spectra and the retention times with those stored in an
in-house library comprising 255 metabolites. Other metabolites were identified using NIST08 (National
Institute of Standards and Technology’s mass spectral database) and the Golm Metabolome Database
(GMD) (http://gmd.mpimp-golm.mpg.de/). Through this approach, 108 compounds were detected
and quantified: 97 were accurately identified and 11 compounds were not identified and were defined
as unknown.
4.3. Statistical Analysis
For the metabolomic analysis, the AMDIS data matrix including 108 metabolites was processed
with the integrated web-based platform MetaboAnalyst 4.0 [http://www.metaboanalyst.ca/] [40].
Missing values were replaced with half of the minimum positive values in the original data, and
after normalization by sum, data were log transformed and categorized using Pareto scaling for the
purposes of analysis, including univariate analysis, partial least square discriminant analysis (PLS-DA),
and its associated variable importance in projection (VIP) score. PLS-DA models were tested with the
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leave-one-out cross validation (LOOCV) method for the evaluation of statistical parameters (correlation
coefficient R2, cross validation coefficient Q2) [41], which allowed us to determine the optimal number
of components for the model description.
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